Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Small molecule shows promise as anti-cancer therapy

14.01.2014
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

In a study described in the January 13 issue of Cancer-Cell, Marikki Laiho, M.D., Ph.D., and her colleagues say their work focused on the ability of a chemical dubbed BMH-21 to sabotage the transcription pathway RNA Polymerase pathway (POL I), shutting down the ability of mutant cancer genes to communicate with cells and replicate.

Laiho's research linked the pathway to p53 gene activity. P53 is a tumor suppressor gene, a protein that regulates cell growth, and it is the most frequently mutated suppressor gene in cancer.

Transcription pathways are the means by which certain proteins that direct cell division are put into action by cells. Uncontrolled cell division is a hallmark of cancer, and BMH-21 has demonstrated an ability to bind to the DNA of cancer cells and completely shut down this transcription pathway.

"Without this transcription machinery, cancer cells cannot function," says Marikki Laiho, M.D., Ph.D., professor of Radiation Oncology and Molecular Radiation Sciences at Johns Hopkins and senior author on the study.

Laiho said BMH-21 was identified using by screening a library of chemical compounds known to have potential for anticancer activity based on their chemical structure and capabilities. Specifically, they looked for the ability of those compounds to interfere with transcription in human tumor cells obtained through the National Cancer Institute's collection of 60 human tumor cell lines of nine different cancer types, including melanoma and colon cancer.

BMH-21 first jumped out, Laiho said, demonstrating potent action against melanoma and colon cancer cells. In fact, in these studies, the drug functioned better in upsetting these cancer cells' activities than many FDA-approved cancer drugs.

BMH-21 also appears to overcome the tendency of cancer cells to resist chemotherapeutic agents because it finds and targets proteins and shuts down the communication pathways that cells use to continue dividing.

"One of the challenges of current cancer therapies, including new targeted therapies, is a cancer cell's ability to overcome a treatment's anticancer properties. The characteristics of a cancer cell and its circuitry is very complex and results in many changes and mutations that allow the cells to continue to thrive despite cancer treatments," said Laiho.

While the findings with BMH-21 are promising, Laiho cautions much more study of the compound is needed before it would be ready for studies in patients. She and her team are continuing studies of the drug in animal models to further reveal the drug's potential against cancer and possible toxicities, and to determine dosage.

The transcription machinery the compound shuts down is common among all cancer cell types, so the researchers believe it has therapeutic potential across many tumor types.

Laiho is currently collaborating with Kimmel Cancer Center drug development experts as well as multiple myeloma blood cancer, medullary thyroid cancer, and prostate cancer experts to further explore the drug's cancer-fighting abilities. She also is collaborating with investigators at a laboratory in Helsinki, Finland, where she maintains an affiliation.

In addition to Laiho, other members of the research team include Karita Peltonen, Laureen Colis, Hester Liu, Rishi Trivedi, Michael S. Moubarek, Henna M. Moore, Bayoan Bai, Michelle Rudek, and Charles J. Bieberich.

The research was supported by the Academy of Finland, Biomedicum Helsinki Foundation, Cancer Society Finland, Finnish Cultural Foundation, Patrick C. Walsh Cancer Research Fund, the National Institutes of Health, Johns Hopkins University start-up funds, and the Analytical Pharmacology Core of the Johns Hopkins Kimmel Cancer Center.

Amy Mone | EurekAlert!
Further information:
http://www.hopkinscancer.org
http://www.hopkinsmedicine.org/radiation_oncology/
http://www.jhmi.edu

More articles from Life Sciences:

nachricht Killer sea snail a target for new drugs
07.07.2015 | University of Queensland

nachricht First images of dolphin brain circuitry hint at how they sense sound
07.07.2015 | Emory Health Sciences

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Surfing a wake of light

Researchers observe and control light wakes for the first time

When a duck paddles across a pond or a supersonic plane flies through the sky, it leaves a wake in its path. Wakes occur whenever something is traveling...

Im Focus: Light-induced Magnetic Waves in Materials Engineered at the Atomic Scale

Researchers explore ultrafast control of magnetism across interfaces: A new study discovers how the sudden excitation of lattice vibrations in a crystal can trigger a change of the magnetic properties of an atomically-thin layer that lies on its surface.

A research team, led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter at CFEL in Hamburg, the University of Oxford, and the...

Im Focus: Viaducts with wind turbines, the new renewable energy source

Wind turbines could be installed under some of the biggest bridges on the road network to produce electricity. So it is confirmed by calculations carried out by a European researchers team, that have taken a viaduct in the Canary Islands as a reference. This concept could be applied in heavily built-up territories or natural areas with new constructions limitations.

The Juncal Viaduct, in Gran Canaria, has served as a reference for Spanish and British researchers to verify that the wind blowing between the pillars on this...

Im Focus: X-rays and electrons join forces to map catalytic reactions in real-time

New technique combines electron microscopy and synchrotron X-rays to track chemical reactions under real operating conditions

A new technique pioneered at the U.S. Department of Energy's Brookhaven National Laboratory reveals atomic-scale changes during catalytic reactions in real...

Im Focus: Iron: A biological element?

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and a half billion years ago.

Think of an object made of iron: An I-beam, a car frame, a nail. Now imagine that half of the iron in that object owes its existence to bacteria living two and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Conference on Regenerative Medicine in Leipzig: Last chance to submit abstracts until 2 July

25.06.2015 | Event News

World Conference on Regenerative Medicine: Abstract Submission has been extended to 24 June

16.06.2015 | Event News

MUSE hosting Europe’s largest science communication conference

11.06.2015 | Event News

 
Latest News

Down to the quantum dot

07.07.2015 | Physics and Astronomy

Tundra study uncovers impact of climate warming in the Arctic

07.07.2015 | Earth Sciences

Transition from 3 to 2 dimensions increases conduction, MIPT scientists discover

07.07.2015 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>